ClinicalTrials.Veeva

Menu

Reinforcing Effects of Marijuana and Opioids

S

Shanna Babalonis, PhD

Status and phase

Enrolling
Phase 1

Conditions

Marijuana Use
Opioid Use

Treatments

Drug: Marijuana
Drug: Opioid

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT05485012
R01DA045700 (U.S. NIH Grant/Contract)
45017-20221

Details and patient eligibility

About

The primary goals of this study are to examine 1) marijuana modulation of oxycodone self-administration and 2) oxycodone modulation of marijuana self-administration, under controlled conditions and across a range of doses for each drug.

Enrollment

12 estimated patients

Sex

All

Ages

18 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Ages 18-50
  • Experience with marijuana and opioids
  • General good health
  • Willing to live at the University of Kentucky Hospital (research unit) for approx. 6.5 weeks (meals are provided,

Exclusion criteria

  • Significant medical complications/conditions

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Quadruple Blind

12 participants in 2 patient groups

Double-blind marijuana/placebo administration
Experimental group
Description:
Participants will receive double-blind administration of vaporized marijuana/placebo
Treatment:
Drug: Opioid
Drug: Marijuana
Double-blind opioid/placebo administration
Experimental group
Description:
Participants will receive double-blind administration of intranasal opioid agonist/placebo
Treatment:
Drug: Opioid
Drug: Marijuana

Trial contacts and locations

1

Loading...

Central trial contact

Paul Nuzzo

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems